In a phase I/II clinical study (NCT01869166) at the Chinese PLA General Hospital, advanced NSCLC patients with over 50% EGFR-positive expression on tumor cells received anti-EGFR CAR-T-cell therapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.